Endonovo Therapeutics (ENDV) 10-Q 19 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 18, 2020
Cover [Abstract]
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	0001528172
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		16,276,076
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 5,256	$ 18,893
Accounts receivable, net of allowance for doubtful accounts of $0	941	22,742
Prepaid expenses and other current assets	3,360	20,920
Total current assets	9,557	62,555
Property, Plant and Equipment, net	3,386	5,915
Patents, net	2,882,724	3,206,180
Total assets	2,895,667	3,274,650
Current liabilities
Accounts payable	609,406	599,470
Accrued interest	1,623,893	1,317,376
Deferred compensation	2,816,859	2,431,373
Notes payable, net of discounts of $31,638 and $12,649 as of June 30, 2020 and December 31, 2019	6,054,091	6,697,146
Notes payable - related party	152,000	165,000
Derivative liability	3,666,938	10,599,690
Series C preferred stock liability, net of discounts $766 at December 31, 2019		1,813,415
Total current liabilities	14,923,187	23,623,470
Acquisition payable	155,000	155,000
Total liabilities	15,078,187	23,778,470
COMMITMENTS AND CONTINGENCIES, note 10
Shareholders' deficit
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 25,000 issued and outstanding at June 30, 2020 and December 31, 2019	25	25
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 7,213,661 and 1,189,204 shares issued and outstanding as of June 30, 2020 and December 31, 2019	1,244	118
Additional paid-in capital	38,056,951	32,432,392
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(50,239,171)	(52,934,786)
Total shareholders' deficit	(12,182,520)	(20,503,820)
Total liabilities and shareholders' deficit	2,895,667	3,274,650
Series B Convertible Preferred Stock [Member]
Shareholders' deficit
Convertible preferred stock	1	1
Series C Convertible Preferred Stock [Member]
Shareholders' deficit
Convertible preferred stock
Series D Convertible Preferred Stock [Member]
Shareholders' deficit
Convertible preferred stock

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Allowance for doubtful accounts receivable	$ 0	$ 0
Discounts on notes payable current	31,638	12,649
Series C preferred stock liability, discounts		$ 766
Super AA super voting preferred stock, par value	$ 0.001	$ 0.001
Super AA super voting preferred stock, shares authorized	1,000,000	1,000,000
Super AA super voting preferred stock, shares issued	25,000	25,000
Super AA super voting preferred stock, shares outstanding	25,000	25,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	7,213,661	1,189,204
Common stock, shares outstanding	7,213,661	1,189,204
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	50,000	50,000
Convertible preferred stock, shares issued	600	600
Convertible preferred stock, shares outstanding	600	600
Series C Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	8,000	8,000
Convertible preferred stock, shares issued	719	1,814
Convertible preferred stock, shares outstanding	719	1,814
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	20,000	20,000
Convertible preferred stock, shares issued	305	255
Convertible preferred stock, shares outstanding	305	255

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	[1]	Jun. 30, 2020	Jun. 30, 2019	[1]
Income Statement [Abstract]
Revenue	$ 44,631	$ 62,729		$ 114,316	$ 107,681
Cost of revenue	11,300	29,573		17,560	37,284
Gross profit	33,331	33,156		96,756	70,397
Operating expenses	635,157	1,007,971		1,378,194	1,858,209
Loss from operations	(601,826)	(974,815)		(1,281,438)	(1,787,812)
Other income (expense)
Change in fair value of derivative liability	(861,147)	(5,470,621)		5,600,255	(5,479,163)
Gain (loss) on settlement of debt	92,492	13,399		(516,783)	52,290
Interest expense, net	(264,170)	(1,405,509)		(1,098,267)	(3,029,086)
Other income (expense)	(1,032,825)	(6,862,731)		3,985,205	(8,455,959)
Income (Loss) before income taxes	(1,634,651)	(7,837,546)		2,703,767	(10,243,771)
Provision for income taxes
Net Income (loss) income	$ (1,634,651)	$ (7,837,546)		$ 2,703,767	$ (10,243,771)
Basic Income (Loss) per share	$ (0.17)	$ (13.57)		$ 0.42	$ (19.33)
Diluted Income (Loss) per share	$ (0.17)	$ (13.57)		$ (0.15)	$ (19.33)
Weighted average common share outstanding:
Basic	9,833,073	577,492		6,368,543	529,924
Diluted	9,833,073	577,492		15,065,162	529,924
[1]	The condensed consolidated financial statements have been retroactively restated to reflect the 1,000-for-1-reverse stock split that occurred on December 20, 2019.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)	Dec. 20, 2019
Income Statement [Abstract]
Reverse stock split	1,000-for-1-reverse stock split

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities:
Net Income (Loss)	$ 2,703,767	$ (10,243,771)	[1]
Adjustments to reconcile net income (loss) to cash used in operating activities:
Depreciation and amortization expense	325,985	325,053
Stock compensation expense	55,540
Fair value of equity issued for services	13,067	92,396
Loss (gain) on extinguishment of debt	516,783	(52,290)	[1]
Amortization of note discount and original issue discount	36,843	1,261,139
Amortization of discount on Series C Preferred stock liability	248	95,429
Non-cash interest expense	550,994	1,077,619
Non-cash value of stock, options and warrants issued for services and notes		47,949
Change in fair value of derivative liability	(5,600,255)	5,479,163	[1]
Changes in assets and liabilities:
Accounts receivable	21,801	(5,081)
Prepaid expenses and other current assets	17,560	(29,944)
Account payable	9,936	123,606
Accrued interest	510,184	513,664
Deferred compensation	385,486	99,212
Net cash used in operating activities	(452,061)	(1,215,856)
Investing activities:
Acquisition of property and equipment		(1,871)
Net cash used in investing activities		(1,871)
Financing activities:
Proceeds from the issuance of notes payable	401,424	1,495,000
Repayments on related-parties short-term advances	(13,000)	(40,000)
Repayments of convertible debt in cash		(130,000)
Proceeds from issuance of common stock and units		61,106
Proceeds from issuance of preferred stock	50,000
Net cash provided by financing activities	438,424	1,386,106
Net (decrease) increase in cash	(13,637)	168,379
Cash, beginning of year	18,893	379,151
Cash, end of period	5,256	547,530
Supplemental disclosure of cash flow information:
Cash paid for interest		81,127
Cash paid for income taxes
Non-Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	1,311,240	2,387,841
Conversion of fixed rate notes to Preferred C Stock		86,600
Conversion of Preferred C Stock to common stock	1,387,601
Issuance of common stock to Preferred C Stock inducement	8,152
Exchange note and accrued interest to new convertible note	$ 316,494
[1]	The condensed consolidated financial statements have been retroactively restated to reflect the 1,000-for-1-reverse stock split that occurred on December 20, 2019.

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - USD ($)		Series AA Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2018	[1]	$ 25	$ 1			$ 43	$ 24,229,945	$ (1,570)	$ (35,620,282)	$ (11,391,838)
Balance, shares at Dec. 31, 2018	[1]	25,000	600			431,063
Common stock issued for cash	[1]						27,559			27,559
Common stock issued for cash, shares	[1]					2,000
Common stock issued for services	[1]						92,084			92,084
Common stock issued for services, shares	[1]					4,132
Valuation of warrants issued with Preferred Stock C							11,512			11,512
Shares issued for conversion of notes payable and accrued interest	[1]					$ 8	2,002,174			2,002,182
Shares issued for conversion of notes payable and accrued interest, shares	[1]					78,044
Valuation of stock issued with notes	[1]						26,545			26,545
Valuation of stock issued with notes, shares	[1]					1,091
Valuation of common stock issued for note extension							8,333			8,333
Valuation of common stock issued for note extension, shares						443
Valuation of stock options issued for services							5,170			5,170
Net loss									(2,406,225)	(2,406,225)
Balance at Mar. 31, 2019	[1]	$ 25	$ 1			$ 51	26,403,322	(1,570)	(38,026,507)	(11,624,678)
Balance, shares at Mar. 31, 2019	[1]	25,000	600			516,773
Balance at Dec. 31, 2018	[1]	$ 25	$ 1			$ 43	24,229,945	(1,570)	(35,620,282)	(11,391,838)
Balance, shares at Dec. 31, 2018	[1]	25,000	600			431,063
Net loss	[1]									(10,243,771)
Balance at Jun. 30, 2019	[1]	$ 25	$ 1			$ 72	29,618,630	(1,570)	(45,864,053)	(16,246,895)
Balance, shares at Jun. 30, 2019	[1]	25,000	600			730,558
Balance at Dec. 31, 2018	[1]	$ 25	$ 1			$ 43	24,229,945	(1,570)	(35,620,282)	(11,391,838)
Balance, shares at Dec. 31, 2018	[1]	25,000	600			431,063
Balance at Dec. 31, 2019		$ 25	$ 1			$ 118	32,432,392	(1,570)	(52,934,786)	(20,503,820)
Balance, shares at Dec. 31, 2019		25,000	600	255		1,189,204
Balance at Mar. 31, 2019	[1]	$ 25	$ 1			$ 51	26,403,322	(1,570)	(38,026,507)	(11,624,678)
Balance, shares at Mar. 31, 2019	[1]	25,000	600			516,773
Common stock issued for cash	[1]						33,547			33,547
Common stock issued for cash, shares	[1]					2,400
Common stock issued for services	[1]						37,813			37,813
Common stock issued for services, shares	[1]					3,025
Valuation of warrants issued with Preferred Stock C	[1]						3,818			3,818
Shares issued for conversion of notes payable and accrued interest	[1]					$ 21	3,134,960			3,134,981
Shares issued for conversion of notes payable and accrued interest, shares	[1]					208,360
Valuation of stock options issued for services							5,170			5,170
Net loss									(7,837,546)	(7,837,546)	[1]
Balance at Jun. 30, 2019	[1]	$ 25	$ 1			$ 72	29,618,630	(1,570)	(45,864,053)	(16,246,895)
Balance, shares at Jun. 30, 2019	[1]	25,000	600			730,558
Balance at Dec. 31, 2019		$ 25	$ 1			$ 118	32,432,392	(1,570)	(52,934,786)	(20,503,820)
Balance, shares at Dec. 31, 2019		25,000	600	255		1,189,204
Reclassification Preferred Series C							2,418,269			2,418,269
Reclassification Preferred Series C, shares					1,814
Shares issued for Preferred Series D							50,000			50,000
Shares issued for Preferred Series D, shares				50
Shares issued for conversion of notes payable and accrued interest						$ 439	2,545,275			2,545,714
Shares issued for conversion of notes payable and accrued interest, shares						4,388,291
Shares issued for conversion of Preferred Series C to common share						$ 164	(164)
Shares issued for conversion of Preferred Series C to common share, shares					(990)	1,636,166
Valuation of stock options issued for services							9,567			9,567
Net loss									4,338,418	4,338,418
Balance at Mar. 31, 2020		$ 25	$ 1			$ 721	37,455,339	(1,570)	(48,596,368)	(11,141,852)
Balance, shares at Mar. 31, 2020		25,000	600	305	824	7,213,661
Balance at Dec. 31, 2019		$ 25	$ 1			$ 118	32,432,392	(1,570)	(52,934,786)	(20,503,820)
Balance, shares at Dec. 31, 2019		25,000	600	255		1,189,204
Net loss										2,703,767
Balance at Jun. 30, 2020		$ 25	$ 1			$ 1,244	38,056,951	(1,570)	(50,239,171)	(12,182,520)
Balance, shares at Jun. 30, 2020		25,000	600	305	719	12,430,418
Balance at Mar. 31, 2020		$ 25	$ 1			$ 721	37,455,339	(1,570)	(48,596,368)	(11,141,852)
Balance, shares at Mar. 31, 2020		25,000	600	305	824	7,213,661
Common stock issued for services						$ 3	3,497			3,500
Common stock issued for services, shares						25,000
Restricted shares issued as inducement to Series C						$ 6	8,146		(8,152)
Restricted shares issued as inducement to Series C, shares						58,428
Shares issued for conversion of notes payable and accrued interest						$ 335	475,627			475,962
Shares issued for conversion of notes payable and accrued interest, shares						3,353,044
Shares issued for conversion of Preferred Series C to common share						$ 99	27			126
Shares issued for conversion of Preferred Series C to common share, shares					(105)	985,322
Commitment shares						$ 39	55,501			55,540
Commitment shares, shares						385,963
Common stock issued with exchange of convertible notes						$ 41	58,814			58,855
Common stock issued with exchange of convertible notes, shares						409,000
Net loss									(1,634,651)	(1,634,651)
Balance at Jun. 30, 2020		$ 25	$ 1			$ 1,244	$ 38,056,951	$ (1,570)	$ (50,239,171)	$ (12,182,520)
Balance, shares at Jun. 30, 2020		25,000	600	305	719	12,430,418
[1]	The condensed consolidated financial statements have been retroactively restated to reflect the 1,000-for-1-reverse stock split that occurred on December 20, 2019.

Condensed Consolidated Statem_5

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) (Parenthetical)	Dec. 20, 2019
Statement of Stockholders' Equity [Abstract]
Reverse stock split	1,000-for-1-reverse stock split

Organization and Nature of Busi

Organization and Nature of Business	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	Note 1 - Organization and Nature of Business Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV). The Company develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders). The Company’s non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical ® ® bioelectricity On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of significant accounting policies Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of June 30, 2020 and 2019 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on May 4, 2020. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The condensed consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation. Going Concern These accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date these condensed consolidated financial statements are issued. As of June 30, 2020, the Company had cash of approximately $5,300 and a working capital deficiency of $14.9 million. During the six months ended June 30, 2020, the Company used approximately $0.5 million of cash in its operation. The Company has incurred recurring losses resulting in an accumulated deficit of approximately $50.2 million as of June 30, 2020. These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these financial statements. During the six months ended June 30, 2020, the Company has raised approximately $0.5 million in debt and equity financing. The Company is raising additional capital through debt and equity securities to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential, future, license agreements, has raised capital through the sale of its preferred and common stock, has entered into an investment agreement whereby the company has access to an equity line of credit and is seeking out profitable companies. In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or ability to raise funds. Reverse Split In October 2019, the Company’s Board of Directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 1,000-for-1 reverse split of the Company’s common stock, which was effected on December 20, 2019. The par value of the common stock was not adjusted as a result of the reverse stock split. Accordingly, all common stock, stock options, warrants and related per share amounts as of and for the quarter ended June 30, 2019 have been retroactively adjusted to give effect to the reverse split. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The components of basic and diluted earnings per share for the six months ended June 30, 2020 and 2019 were as follows: Six months ended June 30, 2020 2019 Numerator: Net income (loss) attributable to common shareholders $ 2,703,767 $ (10,243,771 ) Effect of dilutive securities Convertible notes (4,921,950 ) - Net loss for diluted earnings per share $ (2,218,183 ) $ (10,243,771 ) Denominator: Weighted-average number of common shares outstanding during the period 6,368,643 529,924 Dilutive effect of convertible notes payable 8,696,619 - Common stock and common stock equivalents used for diluted earnings per share 15,065,162 529,924 Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at June 30, 2020 and December 31, 2019. Accounts receivable are written off when all collection attempts have failed. Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the condensed consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company has adopted ASU 2016-02 on January 1, 2019. The adoption of ASU 2016-02 did not have a significant impact on the Company’s condensed consolidated results of operations, financial position and cash flows. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company has early adopted ASU 2018-07 and the adoption did not have a significant impact on the Company’s condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company adopted ASU 2018-13 as of January 1, 2020, and ASU 2018-13 has not had a material impact on the condensed consolidated financial position or results of operations and liquidity. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 3 - Revenue Recognition Contracts with Customers We have adopted ASC 606, Revenue from Contracts with Customers . We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time we have an unconditional right to receive payment. Our sales and sale prices are final and our prices are not affected by contingent events that could impact the transaction price. Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction. Sources of Revenue We have identified the following revenues by revenue source: 1. Medical care providers As of June 30, 2020, and 2019, the sources of revenue were as follows: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Direct sales- Medical care providers, gross $ 44,631 $ 62,729 $ 114,316 $ 107,681 Total sources of revenue $ 44,631 $ 62,729 $ 114,316 $ 107,681 Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Practical Expedients Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 4 – Property, Plant and Equipment The following is a summary of equipment, at cost, less accumulated depreciation at June 30, 2020 and December 31, 2019: June 30, December 31, Autos $ 64,458 $ 64,458 Medical equipment 13,969 13,969 Other equipment 11,367 11,367 89,794 89,794 Less accumulated depreciation 86,408 83,879 $ 3,386 $ 5,915 Depreciation expense for the six months ended June 30, 2020 and 2019 was $2,529 and $1,598, respectively.

Patents

Patents	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 5 – Patents In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $4,500,000. The earliest patents expire in 2024. The following is a summary of patents less accumulated amortization at June 30, 2020 and December 31, 2019: June 30, December 31, 2019 Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 1,617,276 1,293,820 $ 2,882,724 $ 3,206,180 Amortization expense associated with patents was $323,456 and $323,455 for the six months ended June 30, 2020 and 2019, respectively. The estimated future amortization expense related to patents as of June 30, 2020 is as follows: Twelve Months Ending June 30, Amount 2021 $ 646,910 2022 646,910 2023 646,910 2024 646,910 2025 295,084 Total $ 2,882,724

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Notes Payable	Note 6- Notes Payable Notes Payable During the six months ended June 30, 2020, the Company issued five fixed rate promissory notes totaling $800,000 for funding of $401,424 with original terms of six to twelve months and interest rates of 8% to 10%. If the notes are not paid at maturity, two of the five notes will bear a 22% default interest rate and the other three will bear a 24% default interest rate. As of June 30, 2020, all of the new notes remain outstanding and are not in default. During the six months ended June 30, 2020, the Company converted two previous fixed rate notes into variable rate notes in an accumulated amount of $558,250 as a result of the notes not being paid at maturity and, therefore, triggering a conditional conversion option for the noteholder. The conversion rate is 70% and 75% of the Company’s common stock based on the terms included in the variable rate notes. As of June 30, 2020, the Company exchanged one of the variable notes with $316,494 unamortized principal and accrued interest into one fixed rate promissory notes for $525,000 due in twelve months from issuance date and convertible upon an event of default. The Company recorded the exchange in accordance with ASC 470-50 Debt-Modifications and Extinguishments The gross amount of all convertible notes with variable conversion rates outstanding at June 30, 2020 is $4,224,826, of which $163,826 are past maturity. On May 20, 2020, the Company entered into modification and forbearance agreements (the “agreements”) with three investors as a condition for the execution of the equity line purchase agreement (see note 6), collectively totaling $4,397,000 in principal and approximately $1,080,000 in accrued interest. The terms of the agreements include the extension of the maturity date, elimination of the conversion feature attached to the hybrid instrument and a 12.5% premium for future cash redemption. The conversion feature and the cash premium only take effect upon the effectiveness of the registration statement underlying the shares related to the equity line purchase agreement, which did not occur as of June 30, 2020. On July 16, 2020, the Securities and Exchange Commission declared effective the registration statement on Form S-1, which was filed on June 23, 2020 and amended on July 10, 2020. Management reviewed the guidance per ASC 470-60 Troubled debt restructurings Debt-Modifications and Extinguishments Notes payable to a related party in the aggregate amount of $152,000 were outstanding at June 30, 2020 which are past maturity date. The notes bear interest between 10% and 12% per annum. During the six months ended June 30, 2020, the Company paid $13,000 principal to this related party. As of June 30, 2020, fixed rate notes payable outstanding totaled $1,860,903, of which $724,903 is past maturity. June 30, December 31, 2019 Notes payable at beginning of period $ 6,874,795 $ 8,158,198 Notes payable issued 717,918 2,101,000 Loan fees added to note payable 82,082 91,250 Repayments of notes payable in cash (13,000 ) (235,000 ) Less amounts converted to redeemable notes - (67,500 ) Less amounts exchanged to fixed rate notes (283,000 ) - Less amounts converted to stock (1,141,066 ) (3,173,153 ) Notes payable at end of period 6,237,729 6,874,795 Less debt discount (31,638 ) (12,649 ) $ 6,206,091 $ 6,862,146 Notes payable issued to related parties $ 152,000 $ 165,000 Notes payable issued to non-related party $ 6,054,091 $ 6,697,146 The maturity dates on the notes-payable are as follows: Notes to 12 months ending, Related parties Non-related parties Total Past due $ 152,000 $ 888,729 $ 1,040,729 June 30, 2021 - 5,197,000 5,197,000 $ 152,000 $ 6,085,729 $ 6,237,729

Shareholders' Deficit

Shareholders' Deficit	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Shareholders' Deficit	Note 7 - Shareholders’ Deficit Preferred Stock The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows: Number of Shares Number of Shares Outstanding Par Liquidation Authorized at June 30, 2020 Value Value Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 719 $ 0.0001 $ 1,000 Preferred Series D 20,000 305 $ 0.0001 $ 1,000 Undesignated 3,922,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. The Series AA Super Voting Preferred Stockholders will receive no dividends nor any value on liquidation. As of June 30, 2020, there were 25,000 shares of Series AA Preferred stock outstanding. Series B Convertible Preferred Stock On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. As of June 30, 2020, 600 shares of Series B are outstanding. Series C Convertible Redeemable Preferred Stock On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20.00 quarterly dividend commencing March 31, 2018 and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. Management determined that the Series C should be classified as liability per the guidance in ASC 480 Distinguishing Liabilities from Equity as of December 31, 2019. On January 29, 2020, the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B. Management reviewed the guidance in ASC 470-60 Troubled Debt Restructurings and ASC 470-50 Debt-Modifications and Extinguishments Management determined the fair value of the new instrument based on the guidance in ASC 820 Fair Value Measurement. Management concluded that the preferred stock should not be classified as a liability per the guidance in ASC 480 Distinguishing Liabilities from Equity even though the conversion would require the issuance of variable number of shares since such obligation is not unconditional. Management classified the Series C in permanent equity as of June 30, 2020. During the six months ended June 30, 2020, the Company converted 1,041 shares of Series C into 2,621,488 shares of common stock. As of June 30, 2020, there are 719 shares of Series C outstanding. Series D Convertible Preferred Stock On November 11, 2019, the Company filed a certificate of designation for 20,000 shares of Series D Convertible Preferred Stock designated as Series D (“Series D”), which are authorized and convertible, at the option of the holder, at any time from the date of issuance, into shares of common shares. On or prior to August 1, 2020, for each share of Series D, the holder, on conversion, shall receive a number of common shares equal to 0.01% of the Company’s issued and outstanding shares on conversion date and for conversion on or after August 2, 2020, the holder shall receive conversion shares as though the conversion date was August 1, 2020, with no further adjustments for issuances by the Company of common stock after August 1, 2020, except for stock split or reverse stock splits of the common stock. Management classified the Series D in permanent equity as of June 30, 2020. The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders. During the six months ended June 30, 2020, 50 shares of Series D have been issued. As of June 30, 2020, there are 305 shares of Series D outstanding. Common Stock On December 31, 2018, we entered into a non-transferrable investment agreement whereby the investor committed to purchase up to $10,000,000 of our common stock, over the course of 36 months. The aggregate number of shares issuable by us and purchasable by the investor under the investment agreement is 81,250. A registration statement for the sale of our common stock related to the investment agreement went effective on February 11, 2019. On June 2, 2020, in accordance with its undertakings we removed from registration by means of a post-effective amendment all of the securities being registered which remain unsold as the offering has been terminated. The shares removed from registration include all remaining shares under the Equity Purchase Agreement. As adjusted for a subsequent 1,000 for 1 reverse stock split, 15,390 shares were sold under the Registration Statement and 65,860 shares remain unsold. The issuer is withdrawing the 65,860 shares from registration because the issuer does not intend to sell any further shares under the Registration Statement. SEC Notice of Effectiveness was received on June 8, 2020. On May 18, 2020, the Company and Cavalry Fund I LP (the “investor”) entered into an Equity Line Purchase Agreement (“ELPA”) pursuant to which the investor committed to purchase, subject to certain restrictions and conditions, up to $10,000,000 (the “Commitment”) worth of the Company’s common stock, over a period of 24 months from the effectiveness of the registration statement registering the resale of shares purchased by the investor pursuant to the ELPA. The Company agreed to issue shares of its common stock (the “commitment shares”) to the investor having a market value of 5% of the commitment ($500,000 and 3,859,630 shares) based on the market price of the shares at the execution of the ELPA to be delivered in three tranches of 385,963 shares on: (i) the execution of the ELPA; (ii) thirty days after the effectiveness of the registration statement to be filed under the RRA (the “registration right agreement” or the “registration statement”), and (iii) 90 trading days after the effectiveness of the registration statement with the balance of the commitment shares to be issued pro-rata over the first $3,000,000 of puts in accordance with a formula set forth in the ELPA. The ELPA provides that at any time after the effective date of the registration statement and provided the closing sale price of the common shares on the OTCQB is not below $0.01, from time to time on any business day selected by the Company (the “Purchase Date”), the Company shall have the right, but not the obligation, to direct the investor to buy up to 300,000 shares of the common stock (the “regular purchase amount”) at a purchase price equal to the lower of: (i) the lowest applicable sales price on the date of the put and (ii) 85% of the arithmetic average of the 3 lowest closing prices for the common stock during the 10 consecutive trading days ending on the trading day immediately preceding such put date. The regular purchase amount may be increased as follows: to up to 400,000 shares of common stock if the closing price of the common shares is not below $0.25 per share and up to 500,000 shares if the closing price is not below $0.40 per share. Under the ELPA the Company has the right to submit a regular purchase notice to the investor as often as every business day. The payment for the shares covered by each put notice will generally occur on the day following the put notice. The ELPA contains provisions which allow for the Company to make additional puts beyond the regular purchase amount at greater discounts to the market price of the common stock as forth in the ELPA. The ELPA requires the Company to apply at least 50% of the proceeds of puts to the payment of certain variable rate convertible notes issued by the Company. During the six months ended June 30, 2020, pursuant to the execution of the ELPA, the Company issued 385,963 shares of common stock with a value of $55,540. During the six months ended June 30, 2020, the Company issued 7,741,335 shares of common stock for the conversion of notes and accrued interest in the amount of $1,311,240. During the six months ended June 30, 2020, the Company issued 2,621,488 shares of common stock with a value of $1,387,600, related to the conversion of Series C. During the six months ended June 30, 2020, the Company issued 58,428 shares of common stock to Series C with a value of $8,152 to induce the holders to convert into shares of common stock. During the six months ended June 30, 2020, the Company issued 25,000 shares of common stock with a value of $3,500 related to services. During the six months ended June 30, 2020, the Company issued 409,000 shares with a value of $58,855 to one investor to exchange one variable convertible note with remaining principal of $283,000 past maturity for a fixed rate convertible note with principal of $525,000 and maturing one year from issuance. The Company recorded a loss on debt extinguishment of $151,496 for the fair value of the shares issued in accordance with guidance in ASC 470-50 Debt-Modifications and Extinguishments The Variable Debentures issued by the Company each have a provision requiring the Company to reserve a variable amount of shares of common stock for when the holder of the Variable Debenture converts. During the six months ended June 30, 2019, we issued 4,400 shares of common stock in exchange for $61,106 cash pursuant to the Investment Agreement. During the six months ended June 30, 2019, the Company issued 286,404 shares of common stock for the conversion of notes and accrued interest in the amount of $2,387,841. During the six months ended June 30, 2019, the Company issued 443 shares of common stock valued at $8,333 related to the extension of outstanding notes. During the six months ended June 30, 2019, the Company issued 7,157 shares of common stock with a value of $129,897 related to services. During the six months ended June 30, 2019, the Company issued 1,091,000 shares of common stock with a value of $26,545 as additional consideration for the issuance of two promissory notes totaling $336,000. Stock Options The balance of all stock options outstanding as of June 30, 2020 is as follows: Weighted Weighted Average Average Remaining Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2020 99,833 $ 27.81 2.02 - Granted - $ - - - Cancelled (3,300 ) $ 11.60 3.25 - Exercised - $ - - - Outstanding at June 30, 2020 96,533 $ 28.36 1.46 $ - Exercisable at June 30, 2020 96,533 $ 28.36 1.46 $ - On June 11, 2020, the Board of Directors approved the issuance of 74,668,000 non-incentive stock options to officers, directors, and key consultants. The key terms and conditions of the award have not been mutually understood and agreed upon, and as a result, the Company has not recognized stock compensation for such award for the six months ended June 30, 2020. Warrants A summary of the status of the warrants granted under these agreements at June 30, 2020, and changes during the six months then ended is presented below: Outstanding Warrants Weighted Weighted Average Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at January 1, 2020 73,486 $ 306.28 1.37 Granted - $ - - Cancelled (2,408 ) $ 37.89 - Exercised - $ - Outstanding at June 30, 2020 71,078 $ 315.38 0.91 Exercisable at June 30, 2020 71,078 $ 315.38 0.91 The Company measures the fair value of stock options and warrants issued using the Black Scholes option pricing model using the following assumptions: Six months ended June 30, 2020 2019 Expected term - 2 years Exercise price - $14.50-$27.90 Expected volatility - 199%-242% Expected dividends - None Risk-free interest rate - 2.28% to 2.60% Forfeitures - None

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 – Related Party Transactions One former executive of the Company has entered into note payable agreements with the Company. The balance of notes payable from the related party at June 30, 2020 is $152,000. The notes bear interest at between 10%-12% per annum and initially matured on June 30, 2019. On September 29, 2019, the Company extended the maturity on all outstanding notes to December 31, 2019. During the six months ended June 30, 2020, the Company paid $13,000 principal to this related party. As of June 30, 2020, and December 31, 2019, the balance of executives’ deferred compensation is $1,044,475 and $914,853, respectively, of which, $632,257 is related to deferred compensation owed to a former executive of the Company.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 9 – Fair Value Measurements The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Six months ended June 30, 2020 2019 Expected term 1 month 1 month - 1 year Exercise price $0.06-$0.75 $6.20-$12.90 Expected volatility 157%-249% 134%-161% Expected dividends None None Risk-free interest rate 0.03% to 1.54% 1.91% to 2.87% Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the three months ended June 30, 2020: Derivative Liability Balance December 31, 2019 $ 10,599,690 Issuance of convertible debt 524,742 Extinguishment following note exchange (151,496 ) Settlements by debt settlement (1,705,743 ) Change in estimated fair value (5,600,255 ) Balance June 30, 2020 $ 3,666,938 Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at June 30, 2020: Fair Value Measurements Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total As of June 30, 2020 Derivative liability $ - $ - $ 3,666,938 $ 3,666,938 Total $ - $ - $ 3,666,938 $ 3,666,938

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 – Commitments and Contingencies Legal Matters On May 17, 2020, the Company received a letter (the “Letter”) from an attorney representing Auctus Fund, LLC (“Auctus”), a lender to the Company, which claimed that a convertible promissory note in the original principal amount of $275,250 (the “Note”) was “in default”. The Letter, among other things, threatened litigation against the Company and its officers for damages and liquidated damages. On July 23, 2020, the Company was served with a complaint by Auctus filed in the United States District Court for the District of Massachusetts alleging breach of contract and various other theories for recovery and damages. The Company has filed an answer to the complaint and alleged various counterclaims against Auctus. The case in an early stage and the Company intends to vigorously defend against Auctus claims and to pursue its counterclaims against Auctus. The Company may become involved in various legal proceedings in the normal course of business.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2020
Risks and Uncertainties [Abstract]
Concentrations	Note 11 – Concentrations Sales During the six months ended June 30, 2020, we had two significant customers which accounted for 36% and 20% of sales. Supplier We also have a single source for our bioelectric medical devices, which account for 100% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found. Accounts Receivable At June 30, 2020, we had two customer which accounted for 100% of our account receivable balances.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 12 – Subsequent Events Subsequent to June 30, 2020, an aggregate of 611,090 shares of common stock were issued on the conversion of $26,200 of principal and $6,768 of accrued interest pursuant to Variable Notes. Subsequent to June 30, 2020, the Company issued 1,500,000 shares of common stock in exchange for 34,690 previously issued stock options. Subsequent to June 30, 2020, the Company issued 500,000 shares of common stock as inducement for extension of a note with one investor. Subsequent to June 30, 2020, the Company issued 1,234,568 shares of common stock at a purchase price of $0.081 for total consideration of $100,000 to one investor. On July 16, 2020, the Securities and Exchange Commission declared effective the registration statement on Form S-1, which was filed on June 23, 2020 and amended on July 10, 2020 following the execution on May 18, 2020 of the equity line purchase agreement. Subsequent to June 30, 2020, pursuant to the Equity Line Purchase Agreement, the Company issued 385,963 shares of common stock. As a result of these issuances, the total number of common shares outstanding is 16,662,039, Preferred B shares outstanding is 600, Preferred C shares outstanding is 719 and Preferred D shares outstanding is 305.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of June 30, 2020 and 2019 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on May 4, 2020. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The condensed consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern	Going Concern These accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date these condensed consolidated financial statements are issued. As of June 30, 2020, the Company had cash of approximately $5,300 and a working capital deficiency of $14.9 million. During the six months ended June 30, 2020, the Company used approximately $0.5 million of cash in its operation. The Company has incurred recurring losses resulting in an accumulated deficit of approximately $50.2 million as of June 30, 2020. These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these financial statements. During the six months ended June 30, 2020, the Company has raised approximately $0.5 million in debt and equity financing. The Company is raising additional capital through debt and equity securities to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential, future, license agreements, has raised capital through the sale of its preferred and common stock, has entered into an investment agreement whereby the company has access to an equity line of credit and is seeking out profitable companies. In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or ability to raise funds.
Reverse Split	Reverse Split In October 2019, the Company’s Board of Directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 1,000-for-1 reverse split of the Company’s common stock, which was effected on December 20, 2019. The par value of the common stock was not adjusted as a result of the reverse stock split. Accordingly, all common stock, stock options, warrants and related per share amounts as of and for the quarter ended June 30, 2019 have been retroactively adjusted to give effect to the reverse split.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The components of basic and diluted earnings per share for the six months ended June 30, 2020 and 2019 were as follows: Six months ended June 30, 2020 2019 Numerator: Net income (loss) attributable to common shareholders $ 2,703,767 $ (10,243,771 ) Effect of dilutive securities Convertible notes (4,921,950 ) - Net loss for diluted earnings per share $ (2,218,183 ) $ (10,243,771 ) Denominator: Weighted-average number of common shares outstanding during the period 6,368,643 529,924 Dilutive effect of convertible notes payable 8,696,619 - Common stock and common stock equivalents used for diluted earnings per share 15,065,162 529,924
Accounts Receivable	Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at June 30, 2020 and December 31, 2019. Accounts receivable are written off when all collection attempts have failed.
Research and Development	Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the condensed consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company has adopted ASU 2016-02 on January 1, 2019. The adoption of ASU 2016-02 did not have a significant impact on the Company’s condensed consolidated results of operations, financial position and cash flows. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company has early adopted ASU 2018-07 and the adoption did not have a significant impact on the Company’s condensed consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company adopted ASU 2018-13 as of January 1, 2020, and ASU 2018-13 has not had a material impact on the condensed consolidated financial position or results of operations and liquidity. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Schedule of Earnings (Loss) Per Share	The components of basic and diluted earnings per share for the six months ended June 30, 2020 and 2019 were as follows: Six months ended June 30, 2020 2019 Numerator: Net income (loss) attributable to common shareholders $ 2,703,767 $ (10,243,771 ) Effect of dilutive securities Convertible notes (4,921,950 ) - Net loss for diluted earnings per share $ (2,218,183 ) $ (10,243,771 ) Denominator: Weighted-average number of common shares outstanding during the period 6,368,643 529,924 Dilutive effect of convertible notes payable 8,696,619 - Common stock and common stock equivalents used for diluted earnings per share 15,065,162 529,924

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Schedule of Revenue Source	As of June 30, 2020, and 2019, the sources of revenue were as follows: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Direct sales- Medical care providers, gross $ 44,631 $ 62,729 $ 114,316 $ 107,681 Total sources of revenue $ 44,631 $ 62,729 $ 114,316 $ 107,681

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	The following is a summary of equipment, at cost, less accumulated depreciation at June 30, 2020 and December 31, 2019: June 30, December 31, Autos $ 64,458 $ 64,458 Medical equipment 13,969 13,969 Other equipment 11,367 11,367 89,794 89,794 Less accumulated depreciation 86,408 83,879 $ 3,386 $ 5,915

Patents (Tables)

Patents (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents Less Accumulated Amortization	The following is a summary of patents less accumulated amortization at June 30, 2020 and December 31, 2019: June 30, December 31, 2019 Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 1,617,276 1,293,820 $ 2,882,724 $ 3,206,180
Schedule of Estimated Future Amortization Expense	The estimated future amortization expense related to patents as of June 30, 2020 is as follows: Twelve Months Ending June 30, Amount 2021 $ 646,910 2022 646,910 2023 646,910 2024 646,910 2025 295,084 Total $ 2,882,724

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of Notes Payable	As of June 30, 2020, fixed rate notes payable outstanding totaled $1,860,903, of which $724,903 is past maturity. June 30, December 31, 2019 Notes payable at beginning of period $ 6,874,795 $ 8,158,198 Notes payable issued 717,918 2,101,000 Loan fees added to note payable 82,082 91,250 Repayments of notes payable in cash (13,000 ) (235,000 ) Less amounts converted to redeemable notes - (67,500 ) Less amounts exchanged to fixed rate notes (283,000 ) - Less amounts converted to stock (1,141,066 ) (3,173,153 ) Notes payable at end of period 6,237,729 6,874,795 Less debt discount (31,638 ) (12,649 ) $ 6,206,091 $ 6,862,146 Notes payable issued to related parties $ 152,000 $ 165,000 Notes payable issued to non-related party $ 6,054,091 $ 6,697,146
Schedule of Maturity Dates of Notes Payable	The maturity dates on the notes-payable are as follows: Notes to 12 months ending, Related parties Non-related parties Total Past due $ 152,000 $ 888,729 $ 1,040,729 June 30, 2021 - 5,197,000 5,197,000 $ 152,000 $ 6,085,729 $ 6,237,729

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Preferred Stock	The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows: Number of Shares Number of Shares Outstanding Par Liquidation Authorized at June 30, 2020 Value Value Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 719 $ 0.0001 $ 1,000 Preferred Series D 20,000 305 $ 0.0001 $ 1,000 Undesignated 3,922,000 - - -
Schedule of Stock Options Outstanding	The balance of all stock options outstanding as of June 30, 2020 is as follows: Weighted Weighted Average Average Remaining Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2020 99,833 $ 27.81 2.02 - Granted - $ - - - Cancelled (3,300 ) $ 11.60 3.25 - Exercised - $ - - - Outstanding at June 30, 2020 96,533 $ 28.36 1.46 $ - Exercisable at June 30, 2020 96,533 $ 28.36 1.46 $ -
Schedule of Warrants Outstanding	A summary of the status of the warrants granted under these agreements at June 30, 2020, and changes during the six months then ended is presented below: Outstanding Warrants Weighted Weighted Average Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at January 1, 2020 73,486 $ 306.28 1.37 Granted - $ - - Cancelled (2,408 ) $ 37.89 - Exercised - $ - Outstanding at June 30, 2020 71,078 $ 315.38 0.91 Exercisable at June 30, 2020 71,078 $ 315.38 0.91
Schedule of Stock Options Valuation of Assumptions	The Company measures the fair value of stock options and warrants issued using the Black Scholes option pricing model using the following assumptions: Six months ended June 30, 2020 2019 Expected term - 2 years Exercise price - $14.50-$27.90 Expected volatility - 199%-242% Expected dividends - None Risk-free interest rate - 2.28% to 2.60% Forfeitures - None

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Variable Conversion Rate	This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Six months ended June 30, 2020 2019 Expected term 1 month 1 month - 1 year Exercise price $0.06-$0.75 $6.20-$12.90 Expected volatility 157%-249% 134%-161% Expected dividends None None Risk-free interest rate 0.03% to 1.54% 1.91% to 2.87% Forfeitures None None
Schedule of Fair Value of Derivative Liability	The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the three months ended June 30, 2020: Derivative Liability Balance December 31, 2019 $ 10,599,690 Issuance of convertible debt 524,742 Extinguishment following note exchange (151,496 ) Settlements by debt settlement (1,705,743 ) Change in estimated fair value (5,600,255 ) Balance June 30, 2020 $ 3,666,938
Schedule of Recorded Derivative Liability	The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at June 30, 2020: Fair Value Measurements Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total As of June 30, 2020 Derivative liability $ - $ - $ 3,666,938 $ 3,666,938 Total $ - $ - $ 3,666,938 $ 3,666,938

Organization and Nature of Bu_2

Organization and Nature of Business (Details Narrative) - Hanover Portfolio Acquisitions, Inc [Member]	6 Months Ended
	Jun. 30, 2020
Acquisitions description	On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the "Company") received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company's Certificate of Incorporation to change the name of the Company from "Hanover Portfolio Acquisitions, Inc." to "Endonovo Therapeutics, Inc." The name change was affected pursuant to a Certificate of Amendment (the "Certificate of Amendment"), filed with the Secretary of State of Delaware on January 24, 2014.
Common stock, voting rights	Common Stock representing in excess of 50% of the total issued and outstanding voting power

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Dec. 20, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Accounting Policies [Abstract]
Cash		$ 5,300
Working capital deficiency		14,900,000
Net cash used in operating activities		(452,061)	$ (1,215,856)
Accumulated deficit		(50,239,171)		$ (52,934,786)
Proceeds from debt and equity financing		500,000
Reverse stock split	1,000-for-1-reverse stock split
Provision for doubtful accounts		0		$ 0
Research and development expenses		$ 3,283	$ 53,314

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Earnings (Loss) Per Share (Details) - USD ($)	3 Months Ended					6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	[1]	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Accounting Policies [Abstract]
Net income (loss) attributable to common shareholders	$ (1,634,651)	$ 4,338,418	$ (7,837,546)		$ (2,406,225)	$ 2,703,767	$ (10,243,771)	[1]
Convertible notes						(4,921,950)
Net loss for diluted earnings per share						(2,218,183)	(10,243,771)
Weighted-average number of common shares outstanding during the period	9,833,073		577,492			6,368,543	529,924	[1]
Dilutive effect of convertible notes payable						8,696,619
Common stock and common stock equivalents used for diluted earnings per share	9,833,073		577,492			15,065,162	529,924	[1]
[1]	The condensed consolidated financial statements have been retroactively restated to reflect the 1,000-for-1-reverse stock split that occurred on December 20, 2019.

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Revenue Source (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019		Jun. 30, 2020	Jun. 30, 2019
Total sources of revenue	$ 44,631	$ 62,729	[1]	$ 114,316	$ 107,681	[1]
Direct Sales- Medical Care Providers, Gross [Member]
Total sources of revenue	$ 44,631	$ 62,729		$ 114,316	$ 107,681
[1]	The condensed consolidated financial statements have been retroactively restated to reflect the 1,000-for-1-reverse stock split that occurred on December 20, 2019.

Property, Plant and Equipment_2

Property, Plant and Equipment (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,529	$ 1,598

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property and Equipment (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment, gross	$ 89,794	$ 89,794
Less accumulated depreciation	86,408	83,879
Property, Plant and Equipment, net	3,386	5,915
Autos [Member]
Property, Plant and Equipment, gross	64,458	64,458
Medical Equipment [Member]
Property, Plant and Equipment, gross	13,969	13,969
Other Equipment [Member]
Property, Plant and Equipment, gross	$ 11,367	$ 11,367

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Dec. 31, 2017	Jun. 30, 2020	Jun. 30, 2019
Amortization expense		$ 323,456	$ 323,455
Rio Grande Neurosciences, Inc. [Member]
Acquisition of patents	$ 4,500,000
Patents expiration period	2024

Patents - Schedule of Patents L

Patents - Schedule of Patents Less Accumulated Amortization (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,500,000	$ 4,500,000
Less accumulated amortization	1,617,276	1,293,820
Total	$ 2,882,724	$ 3,206,180

Patents - Schedule of Estimated

Patents - Schedule of Estimated Future Amortization Expense (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 646,910
2022	646,910
2023	646,910
2024	646,910
2025	295,084
Total	$ 2,882,724	$ 3,206,180

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019		Jun. 30, 2020	Jun. 30, 2019		May 20, 2020	Dec. 31, 2019	Dec. 31, 2018
Proceeds from note payable				$ 401,424	$ 1,495,000
Gain from debt extinguishment	$ 92,492	$ 13,399	[1]	(516,783)	52,290	[1]
Note payable related parties	152,000			152,000				$ 165,000
Forbearance Agreements [Member] | Three Investors [Member]
Debt instrument face amount							$ 4,397,000
Accrued interest							$ 1,080,000
Debt instrument premium percentage							12.50%
Four Promissory Notes [Member]
Promissory notes	$ 800,000			800,000
Proceeds from note payable				$ 401,424
Debt instrument description				Original terms of six to twelve months and interest rates of 8% to 10%. If the notes are not paid at maturity, two of the five notes will bear a 22% default interest rate and the other three will bear a 24% default interest rate.
Four Promissory Notes [Member] | Minimum [Member]
Debt instrument term				6 months
Debt instrument, interest rate	8.00%			8.00%
Four Promissory Notes [Member] | Maximum [Member]
Debt instrument term				12 months
Debt instrument, interest rate	10.00%			10.00%
Two Promissory Notes [Member]
Debt default interest rate	22.00%			22.00%
Other Two Promissory Notes [Member]
Debt default interest rate	24.00%			24.00%
Two Fixed Rate Notes [Member] | Note Holder [Member]
Debt instrument face amount	$ 558,250			$ 558,250
Two Fixed Rate Notes [Member] | Minimum [Member] | Note Holder [Member]
Debt instrument, interest rate	70.00%			70.00%
Two Fixed Rate Notes [Member] | Maximum [Member] | Note Holder [Member]
Debt instrument, interest rate	75.00%			75.00%
Variable Notes [Member]
Unamortized principal and accrued interest	$ 316,494			$ 316,494
Promissory Notes [Member]
Promissory notes		$ 336,000			$ 336,000
Covertible debt current	525,000			525,000
Gain from debt extinguishment				151,496
Convertible Debentures One [Member]
Convertible debentures outstanding amount	4,224,826			4,224,826
Convertible Debentures One [Member] | Past Maturity [Member]
Convertible debentures outstanding amount	163,826			163,826
Notes Payable [Member]
Promissory notes	6,237,729			6,237,729				$ 6,874,795	$ 8,158,198
Notes Payable [Member] | Related Party [Member]
Note payable related parties	$ 152,000			152,000
Principal payment of debt				$ 13,000
Notes Payable [Member] | Minimum [Member] | Related Party [Member]
Debt instrument, interest rate	10.00%			10.00%
Notes Payable [Member] | Maximum [Member] | Related Party [Member]
Debt instrument, interest rate	12.00%			12.00%
Notes Payable One [Member]
Promissory notes	$ 1,860,903			$ 1,860,903
Notes Payable Two [Member]
Promissory notes	$ 724,903			$ 724,903
[1]	The condensed consolidated financial statements have been retroactively restated to reflect the 1,000-for-1-reverse stock split that occurred on December 20, 2019.

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	3 Months Ended						6 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	[1]	Mar. 31, 2019		Jun. 30, 2020	Dec. 31, 2019
Less amounts converted to stock	$ (475,962)	$ (2,545,714)	$ (3,134,981)		$ (2,002,182)	[1]
Notes Payable [Member]
Notes payable at beginning of period		$ 6,874,795			$ 8,158,198		$ 6,874,795	$ 8,158,198
Notes payable issued							717,918	2,101,000
Loan fees added to note payable							82,082	91,250
Repayments of notes payable in cash							(13,000)	(235,000)
Less amounts converted to redeemable notes								(67,500)
Less amounts exchanged to fixed rate notes							(283,000)
Less amounts converted to stock							(1,141,066)	(3,173,153)
Notes payable at end of period	6,237,729						6,237,729	6,874,795
Less debt discount	(31,638)						(31,638)	(12,649)
Note payable, net	6,206,091						6,206,091	6,862,146
Notes payable issued to related parties	152,000						152,000	165,000
Notes payable issued to non-related party	$ 6,054,091						$ 6,054,091	$ 6,697,146
[1]	The condensed consolidated financial statements have been retroactively restated to reflect the 1,000-for-1-reverse stock split that occurred on December 20, 2019.

Notes Payable - Schedule of Mat

Notes Payable - Schedule of Maturity Dates of Notes Payable (Details)	Jun. 30, 2020USD ($)
Past due	$ 1,040,729
June 30, 2021	5,197,000
Total	6,237,729
Related Parties [Member]
Past due	152,000
June 30, 2021
Total	152,000
Non-Related Parties [Member]
Past due	888,729
June 30, 2021	5,197,000
Total	$ 6,085,729

Shareholders' Deficit (Details

Shareholders' Deficit (Details Narrative) - USD ($)		Jun. 11, 2020	Jun. 02, 2020	May 18, 2020	Jan. 29, 2020	Dec. 22, 2017	Feb. 07, 2017	Feb. 22, 2013	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019		Mar. 31, 2019		Jun. 30, 2020	Jun. 30, 2019		Dec. 31, 2019	Nov. 11, 2019	Dec. 31, 2018
Number of shares authorized									1,000,000						1,000,000			1,000,000
Preferred stock, par value									$ 0.001						$ 0.001			$ 0.001
Preferred stock, outstanding									25,000						25,000			25,000
Loss on debt extinguishment									$ 92,492		$ 13,399	[1]			$ (516,783)	$ 52,290	[1]
Common stock, shares authorized									2,500,000,000						2,500,000,000			2,500,000,000
Shares issued for conversion of notes payable and accrued interest									$ 475,962	$ 2,545,714	3,134,981	[1]	$ 2,002,182	[1]
Issuance of common stock, value	[1]										33,547		27,559
Common stock price per share									$ 0.0001						$ 0.0001			$ 0.0001
Stock issued value conversion of series c									$ 126
Stock issued value conversion of series c induced to convert
Common stock issued for services									3,500		37,813	[1]	$ 92,084	[1]
Common stock issued with exchange of convertible notes									58,855
Gain from debt extinguishment									92,492		13,399	[1]			$ (516,783)	52,290	[1]
Stock option to officers
Board of Director [Member]
Stock option to officers		74,668,000
Variable Notes [Member]
Loss on debt extinguishment															$ 151,496
Convertible debt principle									283,000						283,000
Covertible debt current									525,000						525,000
Gain from debt extinguishment															151,496
Promissory Notes [Member]
Loss on debt extinguishment															151,496
Covertible debt current									$ 525,000						525,000
Gain from debt extinguishment															$ 151,496
Promissory notes											$ 336,000					$ 336,000
Equity Purchase Agreement, Post-Effective Amendment [Member] | Adjustment of Shares [Member]
Number of stock sold during period,shares			15,390
Number of stock unsold during period, shares			65,860
Number of stock, withdraw during period, shares			65,860
Equity Line Purchase Agreement [Member] | Cavalry Fund I LP [Member]
Purchase obligation				$ 10,000,000
Commitment shares to be issued pro-rata				$ 3,000,000
Commitment share description				The ELPA provides that at any time after the effective date of the registration statement and provided the closing sale price of the common shares on the OTCQB is not below $0.01, from time to time on any business day selected by the Company (the "Purchase Date"), the Company shall have the right, but not the obligation, to direct the investor to buy up to 300,000 shares of the common stock (the "regular purchase amount") at a purchase price equal to the lower of: (i) the lowest applicable sales price on the date of the put and (ii) 85% of the arithmetic average of the 3 lowest closing prices for the common stock during the 10 consecutive trading days ending on the trading day immediately preceding such put date. The regular purchase amount may be increased as follows: to up to 400,000 shares of common stock if the closing price of the common shares is not below $0.25 per share and up to 500,000 shares if the closing price is not below $0.40 per share.
Proceeds of puts to the payment				50.00%
Equity Line Purchase Agreement [Member] | Cavalry Fund I LP [Member] | Minimum [Member]
Common stock price per share				$ 0.01
Equity Line Purchase Agreement [Member] | Cavalry Fund I LP [Member] | Tranche One [Member] | Maximum [Member]
Issuance of common stock, value				$ 300,000
Equity Line Purchase Agreement [Member] | Cavalry Fund I LP [Member] | Tranche Two [Member] | Maximum [Member]
Issuance of common stock, value				$ 400,000
Common stock price per share				$ 0.25
Equity Line Purchase Agreement [Member] | Cavalry Fund I LP [Member] | Tranche Three [Member] | Maximum [Member]
Issuance of common stock, value				$ 500,000
Common stock price per share				$ 0.40
Series AA Preferred Stock [Member]
Number of shares authorized								1,000,000
Preferred stock, par value								$ 0.001
Preferred stock voting rights								Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.
Preferred stock, outstanding									25,000						25,000
Series B Convertible Preferred Stock [Member]
Number of shares authorized							50,000
Preferred stock, outstanding									600						600
Stated value dividend							75.00%
Warrants term							3 years
Share exercise price							1.50
Liquidation value of preferred stock, per share							$ 100
Series C Convertible Redeemable Preferred Stock [Member]
Number of shares authorized						8,000
Liquidation value of preferred stock, per share									$ 1,000						$ 1,000
Preferred stock, dividend per share						$ 20
Shares issued, price per share						$ 1,000
Change in rights due to amendmend and restated certificate, description					The Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock.
Convertible preferred stock, shares outstanding									719						719
Loss on debt extinguishment															$ 604,000
Conversion of stock, shares converted															1,041
Gain from debt extinguishment															$ 604,000
Common Stock [Member]
Conversion of stock, shares converted															2,621,488
Obligated for resale amount																				$ 10,000,000
Common stock, shares authorized																				81,250
Average daily volume percentage																				200.00%
Shares issued for conversion of notes payable and accrued interest, shares															7,741,335	286,404
Shares issued for conversion of notes payable and accrued interest															$ 1,311,240	$ 2,387,841
Issuance of common stock															385,963	1,091,000
Issuance of common stock, value															$ 55,540	$ 26,545
Stock issued value conversion of series c															$ 2,621,488
Stock issued value conversion of series c, shares															1,387,600
Stock issued value conversion of series c induced to convert															$ 58,428
Stock issued value conversion of series c induced to convert, shares															8,152
Common stock issued for services															$ 25,000	$ 7,157
Common stock issued for services, shares															3,500	129,897
Common stock issued with exchange of convertible notes															$ 409,000	$ 443
Common stock issued with exchange of convertible notes, shares															58,855	8,333
Common Stock [Member] | Investment Agreement [Member]
Incurred fees																				$ 20,000
Number of shares exchange of common stock, shares																4,400
Number of shares exchange of common stock																$ 61,106
Series D Convertible Preferred Stock [Member]
Number of shares authorized																			20,000
Liquidation value of preferred stock, per share									$ 1,000						$ 1,000
Shares issued for Preferred Series D, shares															50
Convertible preferred stock, shares issued									305						305			255
Convertible preferred stock, shares outstanding									305						305			255
Conversion price percentage																			0.01%
Preferred Stock Designated [Member]
Number of shares authorized									5,000,000						5,000,000
Commitment Shares [Member] | Equity Line Purchase Agreement [Member] | Cavalry Fund I LP [Member] | Tranche One [Member]
Issuance of common stock, value				$ 500,000
Commitment Shares [Member] | Equity Line Purchase Agreement [Member] | Cavalry Fund I LP [Member] | Tranche Two [Member]
Issuance of common stock, value				3,859,630
Commitment Shares [Member] | Equity Line Purchase Agreement [Member] | Cavalry Fund I LP [Member] | Tranche Three [Member]
Issuance of common stock, value				$ 385,963
[1]	The condensed consolidated financial statements have been retroactively restated to reflect the 1,000-for-1-reverse stock split that occurred on December 20, 2019.

Shareholders' Deficit - Schedul

Shareholders' Deficit - Schedule of Preferred Stock (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Number of Shares Authorized	1,000,000	1,000,000
Number of Shares Outstanding	25,000	25,000
Par Value	$ 0.001	$ 0.001
Series AA [Member]
Number of Shares Authorized	1,000,000
Number of Shares Outstanding	25,000
Par Value	$ 0.0010
Liquidation Value
Preferred Series B [Member]
Number of Shares Authorized	50,000
Number of Shares Outstanding	600
Par Value	$ 0.0001
Liquidation Value	$ 100
Preferred Series C [Member]
Number of Shares Authorized	8,000
Number of Shares Outstanding	719
Par Value	$ 0.0001
Liquidation Value	$ 1,000
Preferred Series D [Member]
Number of Shares Authorized	20,000
Number of Shares Outstanding	305
Par Value	$ 0.0001
Liquidation Value	$ 1,000
Undesignated [Member]
Number of Shares Authorized	3,922,000
Number of Shares Outstanding
Par Value
Liquidation Value

Shareholders' Deficit - Sched_2

Shareholders' Deficit - Schedule of Stock Options Outstanding (Details)	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Equity [Abstract]
Stock Option Outstanding, Beginning Balance | shares	99,833
Stock Option Outstanding, Granted | shares
Stock Option Outstanding, Cancelled | shares	(3,300)
Stock Option Outstanding, Exercised | shares
Stock Option Outstanding, Ending Balance | shares	96,533
Stock Option Outstanding, Exercisable Ending Balance | shares	96,533
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 27.81
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares	11.60
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	28.36
Weighted Average Exercise Price, Exercisable Ending Balance | $ / shares	$ 28.36
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	2 years 7 days
Weighted Average Remaining Contractual Term (years), Cancelled	3 years 2 months 30 days
Weighted Average Remaining Contractual Term (years), Outstanding Ending	1 year 5 months 16 days
Weighted Average Remaining Contractual Term (years), Exercisable Ending	1 year 5 months 16 days
Aggregated Intrinsic Value, Outstanding Ending | $
Aggregated Intrinsic Value, Exercisable Ending | $

Shareholders' Deficit - Sched_3

Shareholders' Deficit - Schedule of Warrants Outstanding (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Shares Outstanding, Beginning Balance | shares	73,486
Shares, Granted | shares
Shares, Cancelled | shares	(2,408)
Shares, Exercised | shares
Shares Outstanding, Ending Balance | shares	71,078
Shares Exercisable, Ending Balance | shares	71,078
Weighted-Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 306.28
Weighted-Average Exercise Price, Granted | $ / shares
Weighted average Exercise price, Cancelled | $ / shares	37.89
Weighted-Average Exercise Price, Exercised | $ / shares
Weighted-Average Exercise Price, Outstanding Ending Balance | $ / shares	315.38
Weighted-Average Exercise Price, Exercisable Ending Balance | $ / shares	$ 315.38
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	1 year 4 months 13 days
Weighted Average Remaining Contractual Term (years), Outstanding Ending	10 months 28 days
Weighted Average Remaining Contractual Term (years), Exercisable Ending	10 months 28 days

Shareholders' Deficit - Sched_4

Shareholders' Deficit - Schedule of Stock Options Valuation of Assumptions (Details) - Stock Option and Warrant [Member] - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Expected term	0 years	2 years
Expected dividends		0.00%
Forfeitures		0.00%
Minimum [Member]
Exercise price		$ 14.50
Expected volatility		199.00%
Risk-free interest rate		2.28%
Maximum [Member]
Exercise price		$ 27.90
Expected volatility		242.00%
Risk-free interest rate		2.60%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Sep. 29, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Notes payable - related parties		$ 152,000		$ 165,000
Repayment of related party debt		13,000	$ 40,000
One Former Executive [Member] | Note Payable Agreements [Member]
Notes payable - related parties		$ 152,000
Debt instrument maturity date	Dec. 31, 2019	Jun. 30, 2019
Repayment of related party debt		$ 13,000
One Former Executive [Member] | Note Payable Agreements [Member] | Minimum [Member]
Debt instrument, interest rate		10.00%
One Former Executive [Member] | Note Payable Agreements [Member] | Maximum [Member]
Debt instrument, interest rate		12.00%
Executives [Member] | Note Payable Agreements [Member]
Deferred compensation		$ 1,044,475		914,853
Former Executive Officers [Member] | Note Payable Agreements [Member]
Deferred compensation		$ 632,257		$ 632,257

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Variable Conversion Rate (Details)	6 Months Ended
	Jun. 30, 2020$ / shares	Jun. 30, 2019$ / shares
Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	1 month
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair value assumptions, measurement input, term		1 month
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair value assumptions, measurement input, term		1 year
Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair value assumptions, measurement input, exercise price	$ 0.06	$ 6.20
Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair value assumptions, measurement input, exercise price	$ 0.75	$ 12.90
Measurement Input, Expected Volatility [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentage	157	134
Measurement Input, Expected Volatility [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentage	249	161
Measurement Input, Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentage	0	0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentage	0.03	1.91
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentage	1.54	2.87
Forfeitures [Member]
Fair value assumptions, measurement input, percentage	0	0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Fair Value of Derivative Liability (Details) - Significant Unobservable Inputs (Level 3) [Member]	6 Months Ended
	Jun. 30, 2020USD ($)
Derivative Liability, beginning	$ 10,599,690
Issuance of convertible debt	524,742
Extinguishment following note exchange	(151,496)
Settlements by debt settlement	(1,705,743)
Change in estimated fair value	(5,600,255)
Derivative Liability, ending	$ 3,666,938

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Recorded Derivative Liability (Details)	Jun. 30, 2020USD ($)
Derivative liability	$ 3,666,938
Total	3,666,938
Fair Value, Inputs, Level 1 [Member]
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]
Derivative liability	3,666,938
Total	$ 3,666,938

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	May 17, 2020USD ($)
Auctus Fund, LLC [Member] | Note [Member]
Debt principal amount	$ 275,250

Concentrations (Details Narrati

Concentrations (Details Narrative)	6 Months Ended
	Jun. 30, 2020
Sales Revenue, Net [Member] | Customer One [Member]
Concentration risk, percentage	36.00%
Sales Revenue, Net [Member] | Customer Two [Member]
Concentration risk, percentage	20.00%
Sales Revenue, Net [Member] | Supplier [Member]
Concentration risk, percentage	100.00%
Accounts Receivable [Member] | Two Customer [Member]
Concentration risk, percentage	100.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		2 Months Ended	3 Months Ended
		Aug. 18, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019		Mar. 31, 2019		Dec. 31, 2019
Number of stock issued, value	[1]				$ 33,547		$ 27,559
Common stock, shares outstanding			7,213,661						1,189,204
Preferred stock, outstanding			25,000						25,000
Common Stock [Member]
Stock issued for conversion of debt, shares			3,353,044	4,388,291	208,360	[1]	78,044	[1]
Stock issued for inducement for extension of note, shares			985,322	1,636,166
Number of stock issued, shares	[1]				2,400		2,000
Number of stock issued, value	[1]
Subsequent Event [Member] | Common Stock [Member]
Number of shares exchange of common stock, shares		1,500,000
Number of shares exchange of common stock		$ 34,690
Stock issued for inducement for extension of note, shares		500,000
Number of stock issued, shares		1,234,568
Number of stock issued, value		$ 100,000
Share price, per share		$ 0.081
Common stock, shares outstanding		16,662,039
Subsequent Event [Member] | Common Stock [Member] | Equity Line Purchase Agreement [Member]
Number of stock issued, shares		385,963
Subsequent Event [Member] | Preferred B Stock [Member]
Preferred stock, outstanding		600
Subsequent Event [Member] | Preferred C Stock [Member]
Preferred stock, outstanding		719
Subsequent Event [Member] | Preferred D Stock [Member]
Preferred stock, outstanding		305
Subsequent Event [Member] | Variable Notes [Member]
Stock issued for conversion of debt, shares		611,090
Subsequent Event [Member] | Variable Notes [Member]
Debt principal amount		$ 26,200
Accrued interest		$ 6,768
[1]	The condensed consolidated financial statements have been retroactively restated to reflect the 1,000-for-1-reverse stock split that occurred on December 20, 2019.